IDRAPARINUX SODIUM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C38H55O49S7.9Na
Molecular Weight	1727.177
Optical Activity	UNSPECIFIED
Defined Stereocenters	25 / 25
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[H][C@]5(O[C@H]1[C@H](OC)[C@@H](OC)[C@]([H])(O[C@@H]2[C@@H](COS([O-])(=O)=O)O[C@]([H])(O[C@H]3[C@H](OC)[C@@H](OC)[C@]([H])(O[C@@H]4[C@@H](COS([O-])(=O)=O)O[C@H](OC)[C@H](OS([O-])(=O)=O)[C@H]4OS([O-])(=O)=O)O[C@H]3C([O-])=O)[C@H](OS([O-])(=O)=O)[C@H]2OS([O-])(=O)=O)O[C@@H]1C([O-])=O)O[C@H](COS([O-])(=O)=O)[C@@H](OC)[C@H](OC)[C@H]5OC

InChI

InChIKey=MVPQUSQUURLQKF-MCPDASDXSA-E

InChI=1S/C38H64O49S7.9Na/c1-64-15-12(9-72-88(43,44)45)76-35(27(68-5)18(15)65-2)80-21-19(66-3)28(69-6)37(82-25(21)32(39)40)79-17-14(11-74-90(49,50)51)77-38(31(87-94(61,62)63)24(17)85-92(55,56)57)81-22-20(67-4)29(70-7)36(83-26(22)33(41)42)78-16-13(10-73-89(46,47)48)75-34(71-8)30(86-93(58,59)60)23(16)84-91(52,53)54;;;;;;;;;/h12-31,34-38H,9-11H2,1-8H3,(H,39,40)(H,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63);;;;;;;;;/q;9*+1/p-9/t12-,13-,14-,15-,16-,17-,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30-,31-,34+,35-,36-,37-,38-;;;;;;;;;/m1........./s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18447601 | https://www.ncbi.nlm.nih.gov/pubmed/22111528

Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding. As a result, Sanofi stopped the development of the drug.

Originator

Approval Year

PubMed

Title	Date	PubMed
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.	2008 Jan 26	18294998
Idraparinux and idrabiotaparinux.	2010 Jan	22111528

Sample Use Guides

In Vivo Use Guide

The administration of idraparinux in subcutaneous fixed doses of 2.5 mg once weekly was found to be as effective and safe as conventional antithrombotic therapy in the initial treatment of patients with deep vein thrombosis, but less effective than standard therapy in the initial treatment of patients with primary pulmonary embolism

Route of Administration: Other

Name

Type

Language

IDRAPARINUX SODIUM

Official Name

English

idraparinux sodium [INN]

Common Name

English

IDRAPARINUX SODIUM [MART.]

Common Name

English

Idraparinux sodium [WHO-DD]

Common Name

English

ORG-34006

Code

English

IDRAPARINUX SODIUM [USAN]

Common Name

English

IDRAPARINUX NONASODIUM SALT [MI]

Common Name

English

SANORG-34006

Code

English

SANORG34006

Code

English

IDRAPARINUX NONASODIUM SALT

Common Name

English

METHYL (SODIUM 2,3,4-TRI-O-METHYL-6-O-SULFONATO-.ALPHA.-D-GLUCOPYRANOSYL)-(1->4)-(SODIUM 2,3-DI-O-METHYL-.BETA.-D-GLUCOPYRANOSYLURATE)-(1->4)-(TRISODIUM 2,3,6-TRI-O-SULFONATO-.ALPHA.-D-GLUCOPYRANOSYL)-(1->4)-(SODIUM -2,3-DI-O-METHYL-.ALPHA.-L-IDOPYRANOSY

Common Name

English

Code System Code Type Description

SMS_ID

100000089431